Powered by artificial intelligence, the new Ultrasound Workspace platform reportedly offers advanced echocardiography capabilities and facilitates enhanced diagnostic workflows.
In what may be a significant advance in echocardiography analysis and reporting across multiple systems, Philips launched the Ultrasound Workspace platform at the American College of Cardiology’s Annual Scientific Session and Expo (ACC 2022).
Combining 3D echocardiography capabilities with artificial intelligence (AI)-driven analysis and quantification tools, the Ultrasound Workspace also bolsters connectivity and reporting across different systems with vendor-neutral applications and remote browser access, according to Philips.
“We have combined the power of AI with deep clinical knowledge to create a solution that integrates into the workflows of healthcare providers to help drive efficient clinical decision-making,” noted Jeff Cohen, the senior vice president and global business leader of ultrasound for Philips. “With Ultrasound Workspace, our customers can experience a whole new world of echocardiography workflow to help improve both the patient and staff experience.”
Incorporating quality standards from the American Society of Echocardiography (ASE) and Intersocietal Accreditation Commission (IAC), Philips said the Ultrasound Workspace builds upon the capabilities of Philips’ ultrasound system EPIQ CV with improved efficiency and diagnostic confidence of quantitative measurements such as left ventricular ejection fraction.
Offering flexible licensing for facilities large and small, Philips noted that Ultrasound Workspace is a scalable platform that can be utilized as a stand-alone solution or incorporated into existing PACS and EMR echocardiography workflows.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.